AI Earnings Predictions for Pacira BioSciences Inc. (PCRX)

EX-99.1

2 pcrx-06302026x991.htm

EX-99.1

Document

FOR IMMEDIATE RELEASE

NEWS RELEASE

Pacira BioSciences Reports Second Quarter 2026 Financial Results

-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships --

-- Delivered second quarter total revenue of $192.4 million, representing 6 percent year-over-year growth --

-- Conference call today at 4:30 p.m. ET --

BRISBANE, Calif., August 4, 2026 - Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the second quarter of 2026.

“The first half of 2026 was marked by solid revenue growth and strong execution of our 5x30 strategy across the business,” said Frank D. Lee, chief executive officer of Pacira BioSciences. “Just 18 months into the initiative, we are delivering meaningful progress against each of our strategic objectives to drive long-term growth and create significant value. The quarter was also highlighted by our recently closed transaction with Zimmer Biomet, which positions iovera®° to reach its full global potential while preserving Pacira’s participation in its future success and further sharpening our focus as an innovation-driven biopharmaceutical company.”

Second Quarter 2026 Financial Highlights

•Second quarter revenues of $192.4 million

•Second quarter GAAP net income of $4.7 million, or $0.12 per share (basic and diluted)

•Second quarter adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $48.7 million

•Second quarter non-GAAP net income of $29.5 million, or $0.75 per share (basic) and $0.73 per share (diluted)

See “Non-GAAP Financial Information” below.

Recent Business Highlights

•Divestiture of iovera° Business to Zimmer Biomet. Pacira recently completed the divestiture of its iovera° business to Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader. Under the terms of the transaction, Pacira will receive up to $140 million with an upfront payment of $70 million, subject to customary adjustments, and potential future revenue-based milestone payments totaling up to an additional $70 million during the period up to and through December 31, 2031. The parties will collaborate on advancing the spasticity program with an opportunity for Pacira to receive incremental compensation assuming successful completion of the registrational study and subsequent regulatory approval. The transaction closed on July 31, 2026 and the Company received cash of $73.6 million, after purchase price adjustments.

•UnitedHealthcare Now Providing Separate Reimbursement for EXPAREL. UnitedHealthcare is now providing separate reimbursement for EXPAREL® (bupivacaine liposome injectable suspension) across outpatient settings, including hospital outpatient departments and ambulatory surgery centers. This update enables EXPAREL to be reimbursed outside of the surgical bundle for eligible UnitedHealthcare members, representing an additional step in expanding access to non-opioid postsurgical pain management options. With approximately 40 million covered lives, UnitedHealthcare is the largest health insurer in the United States.

•Advancement of PCRX-201 Development Program. PCRX-201 (enekinragene inzadenovec), our investigational, locally administered, gene therapy for osteoarthritis of the knee, has successfully transitioned to a scalable commercial manufacturing process intended to support future registrational development and commercialization. Following implementation of the new process and availability of clinical supply, enrollment is underway in Part B of the Phase 2 ASCEND study. Enrollment in Part A concluded in June, with topline data expected by the end of 2026.

•Leading Peer-Reviewed Rheumatology Journal to Publish Phase 1 Study of PCRX-201. Our Phase 1 study of PCRX-201 has been accepted for publication in the Annals of the Rheumatic Diseases journal in a paper entitled “Safety, Biodistribution, and Exploratory Clinical Outcomes of a Novel Intraarticular IL-1Ra Gene Therapy (PCRX-201) in Moderate-to-Severe Knee Osteoarthritis: 2-Year Results of a Phase 1 Study”. The lead author is Dr. Stanley Cohen, a leading rheumatologist and Clinical Professor at the University of Texas Southwestern Medical Center.

•Real-world Study Highlights Benefits of EXPAREL in TSA Procedures. Findings from a real-world study were presented at ISPOR 2026. ISPOR is recognized as the global leader in the field of health economics and outcomes research excellence. The study evaluated outcomes associated with the use of EXPAREL following outpatient total shoulder arthroplasty (TSA) in Medicare Advantage patients. Findings showed lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events associated with EXPAREL use. The retrospective analysis a

EX-99.1

2 pcrx-03312026x991.htm

EX-99.1

Document

FOR IMMEDIATE RELEASE

NEWS RELEASE

Pacira BioSciences Reports First Quarter 2026 Financial Results

-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent --

-- Completed enrollment in Phase 3 registrational study of ZILRETTA in osteoarthritis pain of the shoulder; study on track for topline readout by end of year --

-- Conference call today at 4:30 p.m. ET --

BRISBANE, Calif., April 30, 2026 - Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the first quarter of 2026.

“Pacira entered 2026 with strong momentum as our 5x30 strategy continues to generate clear and measurable results,” said Frank D. Lee, chief executive officer of Pacira BioSciences. “In the first quarter, we delivered solid topline performance, highlighted by renewed growth across our commercial portfolio. This performance is fueled by a powerful combination of expanding market access, growing awareness and adoption, and mounting real world evidence, all of which are reinforcing each other.”

“Importantly, we are now entering a data-rich period, with key readouts this year expected from Part A of our Phase 2 study of PCRX-201 in knee osteoarthritis, as well as our registrational studies for ZILRETTA in shoulder osteoarthritis and iovera° in spasticity. As we move through 2026, we will continue to execute our 5x30 strategy to drive durable revenue growth, deliver clinical innovation, and create long-term value for patients and shareholders into and beyond 2030,” continued Mr. Lee.

First Quarter 2026 Financial Highlights

•First quarter revenues of $177.4 million

•First quarter GAAP net income of $2.9 million, or $0.07 per share (basic and diluted)

•First quarter adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $40.2 million

•First quarter non-GAAP net income of $24.5 million, or $0.60 per share (basic and diluted)

•Repurchased 2.2 million shares of common stock at an average price of $22.28 per share, for a cost of $50.0 million

See “Non-GAAP Financial Information” below.

Recent Business Highlights

•Patient Enrollment Concluded in Phase 3 Registration Study Evaluating Safety and Efficacy of ZILRETTA for the Treatment of Shoulder Osteoarthritis. In April 2026, the company concluded patient enrollment in its Phase 3 registration study of ZILRETTA for osteoarthritis, or OA, pain of the shoulder. The company expects to report topline results later this year. If the study is successful, ZILRETTA could be the first product with an on-label indication for OA pain of the shoulder.

•Real-world EXPAREL Data Shows Lower Total Healthcare Costs in Outpatient THA and TKA Procedures. In April 2026, the company presented data from three real-world studies supporting the economic value of EXPAREL in total hip arthroplasty (THA) and total knee arthroplasty (TKA) procedures performed in hospital outpatient department (HOPD) settings at the Academy of Managed Care Pharmacy Annual 2026 Meeting. Across the analyses, EXPAREL use was associated with lower or comparable total healthcare costs and reduced opioid utilization in certain patient populations over follow-up periods of up to six months.

•Two Real-world Studies Highlight Benefits of EXPAREL in TKA and Spinal Fusion Procedures. In March 2026, the company presented findings from real-world studies evaluating the benefits of EXPAREL in orthopedic procedures, including TKA and spinal fusion. In both studies, EXPAREL was associated with lower total cost of care compared with ropivacaine in one study and non-liposomal bupivacaine standard of care in the other, with reductions observed in both outpatient and inpatient surgical settings. The data were presented at the Orthopaedic Research Society 2026 Annual Meeting.

•Two Real-world Studies from IGOR Registry Highlight Clinical Effectiveness of EXPAREL for TKA and Long-term Pain Management with iovera° for OA of the Knee. In March 2026, the company presented real-world evidence from its Innovations in Genicular Outcomes Registry, or IGOR, a first-of-its-kind multicenter, prospective, longitudinal registry. The first study demonstrated EXPAREL was associated with improvements in pain, opioid use, function, and length of stay following TKA as compared to patients who received conventional bupivacaine and ropivacaine. The second study demonstrated cryoneurolysis treatment with iovera° was associated with longer-term improvement in pain and function for up to 12 months, relative to a typical improvement of outcomes for 4 to 6 months following alternative intra-articular agents. The data were presented at the American Academy of Orthopedic Surgeons 2026 Annual Meeting.

First Quarter 2026 Financia

pcrx-202602260001396814false00013968142026-02-262026-02-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 26, 2026

PACIRA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware001-3506051-0619477 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)

2000 Sierra Point Parkway, Suite 900 Brisbane, California 94005 (Address and Zip Code of Principal Executive Offices)

(650) 242-8052 (Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading symbolName of each exchange on which registered Common Stock, par value $0.001 per sharePCRXNasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On February 26, 2026, Pacira BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full-year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit NumberDescription

99.1Press Release dated February 26, 2026

104Cover Page Interactive Data File (Formatted as Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PACIRA BIOSCIENCES, INC.

(REGISTRANT)

Dated:February 26, 2026By:/s/ KRISTEN WILLIAMS Kristen Williams Chief Administrative Officer and Secretary